EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Spike and nucleocapsid antibody dynamics following SARS ‐ CoV ‐2 infection and vaccination: Implications for sourcing COVID ‐19 convalescent plasma from routinely collected blood donations

Clara Di Germanio iD, Xutao Deng, Brendan G Balasko, Graham Simmons iD, Rachel Martinelli, Eduard Grebe iD, Mars Stone, Bryan R Spencer iD, Paula Saa iD, Elaine A Yu, Marion C Lanteri, Valerie Green und 7 weitere

Transfusion · 2024

DOI: 10.1111/trf.18017 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Transfusion, 2024. Verfasst von Clara Di Germanio und 18 weiteren Autor:innen. Beteiligte Einrichtung: Vitalant Research Institute, San Francisco, California, USA. Hauptthemen laut MEDLINE: Blood Donors, COVID-19, SARS-CoV-2, Antibodies, Viral. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: CDC HHS, Centers for Disease Control and Prevention.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

COVID‐19 convalescent plasma (CCP) remains a treatment option for immunocompromised patients; however, the current FDA qualification threshold of ≥200 BAU/mL of spike antibody appears to be relatively low. We evaluated the levels of binding (bAb) and neutralizing antibodies (nAb) on serial samples from repeat blood donors who were vaccinated and/or infected to inform criteria for qualifying CCP from routinely collected plasma components.

Methods

Donors were categorized into four groups: (1) infected, then vaccinated, (2) vaccinated then infected during the delta, or (3) omicron waves, (4) vaccinated without infection. IgG Spike and total Nuclecapsid bAb were measured, along with S variants and nAb titers using reporter viral particle neutralization.

Results

Mean S IgG bAb peaks after infection alone were lower than after primary and booster vaccinations, and higher after delta and omicron infection in previously vaccinated donors. Half‐lives for S IgG ranged from 34 to 66 days after first infection/vaccination events and up to 108 days after second events. The levels of S IgG bAb and nAb were similar across different variants, except for omicron, which were lower. Better correlations of nAb with bAb were observed at higher levels (hybrid immunity) than at the current FDA CCP qualifying threshold.

Discussion

Routine plasma donations from donors with hybrid immunity had high S bAb and potent neutralizing activity for 3–6 months after infection. In donations with high (>4000 BAU/mL) S IgG, >95% had high nAb titers (>500) against ancestral and variant S, regardless of COVID‐19 symptoms. These findings provide the basis for test‐based criteria for qualifying CCP from routine blood donations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Blood DonorsCOVID-19SARS-CoV-2Antibodies, ViralAntibodies, NeutralizingCOVID-19 SerotherapySpike Glycoprotein, CoronavirusCOVID-19 VaccinesImmunoglobulin GHumansImmunization, PassiveMaleFemaleVaccinationAdultMiddle AgedBlood Donation

Stichwörter der Autor:innen

immunology (other than RBC serology)infectious disease testing

Substanzen

Antibodies, ViralAntibodies, NeutralizingSpike Glycoprotein, CoronavirusCOVID-19 VaccinesImmunoglobulin Gspike protein, SARS-CoV-2

Autor:innen und Institutionen

  • Vitalant Research Institute, San Francisco, California, USA.
  • Department of Laboratory Medicine, University of California San Francisco, San Francisco, California, USA.
  • American Red Cross, Scientific Affairs, Dedham, Massachusetts, USA.
  • American Red Cross, Scientific Affairs, Rockville, Maryland, USA.
  • Creative Testing Solutions, Tempe, Arizona, USA.
  • Westat, Rockville, Maryland, USA.

ORCID-Profile: Clara Di Germanio, Graham Simmons, Eduard Grebe, Bryan R Spencer, Paula Saa, Jefferson Jones, Michael P Busch

Förderung

  • CDC HHS
  • Centers for Disease Control and Prevention

Zitieren

APA

Di Germanio, C., Deng, X., Balasko, B. G., Simmons, G., Martinelli, R., Grebe, E., Stone, M., Spencer, B. R., Saa, P., Yu, E. A., Lanteri, M. C., Green, V., Wright, D., Lartey, I., Kleinman, S., Jones, J., Biggerstaff, B. J., Contestable, P., & Busch, M. P. (2024). Spike and nucleocapsid antibody dynamics following SARS ‐ CoV ‐2 infection and vaccination: Implications for sourcing COVID ‐19 convalescent plasma from routinely collected blood donations. Transfusion. https://doi.org/10.1111/trf.18017

Vancouver

Di Germanio C, Deng X, Balasko BG, Simmons G, Martinelli R, Grebe E, et al. Spike and nucleocapsid antibody dynamics following SARS ‐ CoV ‐2 infection and vaccination: Implications for sourcing COVID ‐19 convalescent plasma from routinely collected blood donations. Transfusion. 2024. doi:10.1111/trf.18017

BibTeX
@article{DiGermanio2024,
  author = {Di Germanio, Clara and Deng, Xutao and Balasko, Brendan G and Simmons, Graham and Martinelli, Rachel and Grebe, Eduard and Stone, Mars and Spencer, Bryan R and Saa, Paula and Yu, Elaine A and Lanteri, Marion C and Green, Valerie and Wright, David and Lartey, Isaac and Kleinman, Steven and Jones, Jefferson and Biggerstaff, Brad J and Contestable, Paul and Busch, Michael P},
  title = {Spike and nucleocapsid antibody dynamics following SARS ‐ CoV ‐2 infection and vaccination: Implications for sourcing COVID ‐19 convalescent plasma from routinely collected blood donations},
  journal = {Transfusion},
  year = {2024},
  doi = {10.1111/trf.18017}
}
Kostenlos starten →